Ironwood Pharmaceuticals, Inc. (IRWD) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-02-26
Business type: Asset play
How it makes money
Partners pay for LINZESS sales, with profits moving based on net price and inventory fluctuations.
Partners like AbbVie pay Ironwood based on LINZESS sales; the resulting profit is driven by net price and inventory fluctuations.
This collaborative model means revenue depends on how much product moves through distribution channels and the price negotiated for it.
What growth costs
The company must fund clinical trials for new drugs like apraglutide to grow.
To expand beyond its current product, the company must fund significant clinical trials.
It is currently advancing apraglutide through upcoming Phase III trials.
What could damage it
Changes in insurance coverage or reimbursement levels could permanently harm its revenue.
Because patients rely on insurance to afford medication, any reduction in coverage from government or private payors impacts the ability to sell the drug.
This creates a causal chain where shifts in third-party reimbursement directly impair the company's earnings.
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.